Saredutant
From Wikipedia, the free encyclopedia
 |
|
|
Saredutant
|
|
| Systematic (IUPAC) name | |
| N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C31H35Cl2N3O2 |
| Mol. mass | 552.5345 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Saredutant, or SR 48968, is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by sanofi-aventis. Its mechanism of action is different from antidepressants currently available on the market. It works by blocking the effects of Neurokinin A at the NK-2 receptor.
Phase III studies are currently being conducted.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||
